Future options with capecitabine (Xeloda) in (neo)adjuvant treatment of breast cancer

Seminars in Oncology

Volumn 31, Issue SUPPL. 10, 2004, Pages 45-50

  Fumoleau, Pierre ^a   Cameron, David ^b  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ALOPECIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; NAUSEA AND VOMITING; NEUTROPENIA; PRIORITY JOURNAL; SEPSIS;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS; DEOXYCYTIDINE; HUMANS; NEOADJUVANT THERAPY;

EID: 5644271512     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.07.021     Document Type: Conference Paper

References (44)

1. J.L. Blum, S.E. Jones, A.U. Buzdar Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer J Clin Oncol 17 1999 485 493
2. J.L. Blum, V. Dieras, P.M. Lo Russo Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients Cancer 92 2001 1759 1768
3. P. Reichardt, G. von Minckwitz, P.C. Thuss-Patience Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer, relapsing after treatment with a taxane-containing therapy Ann Oncol 14 2003 1227 1233
4. P. Fumoleau, R. Largillier, C. Clippe Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer Eur J Cancer 40 2004 536 542
5. J. O'Shaughnessy, J. Blum, V. Moiseyenko Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer Ann Oncol 12 2001 1247 1254
6. J. O'Shaughnessy, D. Miles, S. Vukelja Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer phase III trial results J Clin Oncol 20 2002 2812 2823
7. D. Talbot, V. Moiseyenko, S. Van Belle Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines Br J Cancer 86 2002 1367 1372
8. M. Miwa, M. Ura, M. Nishida Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue Eur J Cancer 34 1998 1274 1281
9. M. Endo, N. Shinbori, Y. Fukase Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5′-deoxy-5- fluorouridine by cyclophosphamide in mammary tumor models Int J Cancer 83 1999 127 134
10. K. Fujimoto-Ouchi, F. Sekiguchi, Y. Tanaka Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5′-dFUrd in human breast cancer models Cancer Chemother Pharmacol 49 2002 211 216
11. N. Sawada, T. Ishikawa, Y. Fukase Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts Clin Cancer Res 4 1998 1013 1019
12. N. Sawada, T. Ishikawa, F. Sekiguchi X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts Clin Cancer Res 5 1999 2948 2953
13. N. Sawada, K. Fujimoto-Ouchi, T. Ishikawa Antitumour activity of combination therapy with capecitabine plus vinorelbine, and capecitabine plus gemcitabine in human tumour xenograft models [abstract 5388] Proc Am Assoc Cancer Res 43 2002 1088
14. B.-Q. Shen, S. Stainton, D. Li Combination of Avastin and Xeloda synergistically inhibits colorectal tumor growth in a Colo205 tumor xenograft model [abstract 2203] Proc Am Assoc Cancer Res 45 2004 508
15. N. Batista, G. Perez-Manga, M. Constenla Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer Br J Cancer 90 2004 1740 1746
16. W.J. Gradishar, L.A. Meza, B. Amin Capecitabine plus paclitaxel as front line combination therapy for metastatic breast cancer a multicenter phase II study J Clin Oncol 22 2004 2321 2327
17. H.G. Lee, J.J. Lee, J.H. Oh Phase III randomized trial of primary chemotherapy with doxorubicin/ cyclophosphamide (AC) vs. docetaxel/capecitabine (TX) for stage II/III breast cancer (BC) interim analysis [abstract 607] Proc Am Soc Clin Oncol 23 2004 28a
18. W. Scheithauer, J. Blum Coming to grips with hand-foot syndrome insights from clinical trials evaluating capecitabine Oncology (Huntingt) 18 2004 1161 1173
19. F. Nolé, F. de Braud, M. Aapro Phase I-II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer a regimen with a low subjective toxic burden Ann Oncol 8 1997 865 870
20. F. Nolé, I. Minchella, M. Colleoni Primary chemotherapy in operable breast cancer with favorable prognostic factors a pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN) Ann Oncol 10 1999 993 996
21. G.V. Kornek, K. Haider, W. Kwasny Effective treatment of advanced breast cancer with vinorelbine, 5-fluorouracil and l-leucovorin plus human granulocyte colony-stimulating factor Br J Cancer 78 1998 673 678
22. G. von Minckwitz, G. Raab, J.U. Blohmer In vivo-chemosensitivity adapted primary chemotherapy in patients with primary breast cancer. Results of the Gepartrio-Pilot trial [abstract 371] Eur J Cancer 1 suppl 5 2003 S114
23. E.P. Mamounas Neoadjuvant chemotherapy for operable breast cancer is this the future? Clin Breast Cancer 4 2003 S10 S19
24. Early Breast Cancer Trialists' Collaborative Group Polychemotherapy for early breast cancer an overview of the randomised trials Lancet 352 1998 930 942
25. G.N. Hortobagyi, F.C. Ames, A.U. Buzdar Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy Cancer 62 1988 2507 2516
26. J.A. van der Hage, C.J. van de Velde, J.P. Julien Preoperative chemotherapy in primary operable breast cancer results from the European Organization for Research and Treatment of Cancer trial 10902 J Clin Oncol 19 2001 4224 4237
27. L. Gianni, J. Baselga, W. Eiermann First report of the European Cooperative Trial in operable breast cancer (ECTO) effects of primary systemic therapy (PST) on local-regional disease [abstract 132] Proc Am Soc Clin Oncol 21 2002 34a
28. I.E. Smith, G. Walsh, A. Jones High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer J Clin Oncol 13 1995 424 429
29. D.J. Kuter Thrombotic complications of central venous catheters in cancer patients Oncologist 9 2004 207 216
30. S.A. Payne A study of quality of life in cancer patients receiving palliative chemotherapy Soc Sci Med 35 1992 1505 1509
31. M. Verso, G. Agnelli Venous thromboembolism associated with long-term use of central venous catheters in cancer patients J Clin Oncol 21 2003 3665 3675
32. C.E. Nightingale, A. Norman, D. Cunningham A prospective analysis of 949 long-term central venous access catheters for ambulatory chemotherapy in patients with gastrointestinal malignancy Eur J Cancer 33 1997 398 403
33. R.L. Poorter, F.N. Lauw, W.A. Bemelman Complications of an implantable venous access device (Port-a-Cath) during intermittent continuous infusion of chemotherapy Eur J Cancer 32 1996 2262 2266
34. H. Bonnefoi, L. Biganzoli, L. Mauriac An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (CEX) as primary treatment for large operable or locally advanced/inflammatory breast cancer Eur J Cancer 39 2003 1277 1283
35. M. Venturini, A. Durando, O. Garrone Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma Cancer 97 2003 1174 1180
36. O. Pagani, C. Sessa, S. Longhi Dose-finding study of docetaxel (T) and doxorubicin (A) day 1 and 8 plus capecitabine (X) day 1 to 14 (TAX) as first line treatment in advanced breast cancer (ABC) [abstract 711] Eur J Cancer 37 suppl 6 2001 194
37. J.D. Ahlgren, E. Lidbrink, B. Lind Phase II study of epirubicin, cisplatin and capecitabine as neo-adjuvant chemotherapy in women with locally advanced or inflammatory breast cancer [abstract 107] Proc Am Soc Clin Oncol 22 2003 27
38. M. Ghosn, J. Kattan, F. Farhat Navelbine (N) capecitabine (C) combination (Navcap); the new first line chemotherapy regimen for metastatic breast cancer (MBC) results of phase II trial [abstract 531] Breast Cancer Res Treat 76 suppl 1 2002 133
39. A. Welt, G. von Minckwitz, D. Borquez Extended phase I study of capecitabine in combination with vinorelbine in pretreated patients with advanced breast cancer [abstract 336] Breast Cancer Res Treat 76 suppl 1 2002 S90
40. N. Stuart, J.L. Bishop, S.R.D. Johnson Vinorelbine and capecitabine (VX) for advanced breast cancer - A phase II study showing good activity and potential for further development [abstract 183] Proc Am Soc Clin Oncol 22 2003 46a
41. J. Ahn, H. Ahn, S. Kim Phase II study of capecitabine and vinorelbine in anthracycline and taxane pretreated breast cancer patients final results [abstract 216] Proc Am Soc Clin Oncol 22 2003 54
42. D. Sambiasi, A. Misino, N. Silvestris A phase I study of vinorelbine plus capecitabine in patients with advanced breast cancer [abstract 200P] Ann Oncol 13 suppl 5 2002 56
43. A.F. Schott, D.F. Hayes, V. Stearns Vinorelbine (VR) and capecitabine (CAP) in metastatic breast cancer phase I/II study with correlative genotype, phenotype and pharmacokinetics [abstract 338] Breast Cancer Res Treat 76 suppl 1 2002 S91
44. F. Nussey, J. Afseth, E. Murray Dose-finding study of the combination of oral idarubicin and oral capecitabine in the treatment of locally advanced or advanced breast cancer [abstract 278] Eur J Cancer 3 suppl 2 2004 137